{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:01Z","timestamp":1785544981822,"version":"3.56.0"},"reference-count":24,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Atopic dermatitis (AD) is a common inflammatory skin disease associated with substantial disease burden. Traditional Chinese medicine (TCM) has shown beneficial effects in improving AD symptoms and reducing recurrence. Inflammation Formula Number 1 (IFN-1), a TCM prescription consisting of 10 herbal ingredients, has demonstrated favorable efficacy in clinical practice. However, traditional decoction preparation is time-consuming and inconvenient for long-term standardized use. Granule formulations may improve convenience, stability, and quality control, but their dose-response relationship and equivalence to traditional decoction remain unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This multicenter, prospective, randomized equivalence trial aims to evaluate the efficacy, safety, and dose-response relationship of IFN-1 granule formulations compared with traditional decoction in patients with mild to moderate AD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A total of 300 patients with mild to moderate AD aged 18 to 60 years will be recruited from 5 hospitals between April 2026 and January 2027. Participants will be randomly assigned in a 2:2:1:1 ratio to the traditional decoction group (n=100, 33.3%), standard-dose granule group (n=100, 33.3%), two-thirds dose granule group (n=50, 16.7%), or one-tenth dose granule group (n=50, 16.7%). All groups will receive 4 weeks of treatment. The primary end point is the proportion of patients achieving at least 50% improvement in the Eczema Area and Severity Index (EASI) at week 4. Secondary outcomes include EASI75, EASI90, Investigator Global Assessment score of 0 or 1, body surface area involvement, Dermatology Life Quality Index, pruritus numerical rating scale, Patient-Oriented Eczema Measure, and TCM syndrome scores. Outcomes will be assessed at baseline and weeks 1, 2, and 4. Statistical analyses will be conducted using SAS (version 9.4). Equivalence will be evaluated using a 2-sided 95% CI approach with a predefined equivalence margin of \u221215% to +15%.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Funding for this study was obtained in 2025. Ethical approval was granted by the Ethics Committee of Shanghai Skin Disease Hospital in December 2025, and the trial was registered with the International Traditional Medicine Clinical Trial Registry (ITMCTR2026000452). Participant recruitment is scheduled to begin in April 2026 and continue through January 2027. No patients were recruited at the time of manuscript submission. Data analysis is expected to commence in March 2027, and the primary study findings are anticipated to be published in 2028.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This trial will determine whether IFN-1 granules achieve efficacy comparable to traditional decoction while improving treatment convenience. The findings may provide evidence for dose optimization and standardized clinical application of TCM granule formulations in AD management.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/96094","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:30:16Z","timestamp":1783092616000},"page":"e96094-e96094","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Dose-Response of Inflammation Formula Number 1 Granules Versus Traditional Decoction in the Treatment of Patients With Mild to Moderate Atopic Dermatitis: Protocol for a Multicenter Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-7768","authenticated-orcid":false,"given":"Ding","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1924","authenticated-orcid":false,"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4103-5229","authenticated-orcid":false,"given":"Chuanbing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-9679","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4217-0214","authenticated-orcid":false,"given":"Yang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3733-687X","authenticated-orcid":false,"given":"Wencheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7041-3235","authenticated-orcid":false,"given":"Guangpu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3316-4538","authenticated-orcid":false,"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1911-9691","authenticated-orcid":false,"given":"Fanlingzi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-7970","authenticated-orcid":false,"given":"Xiangjin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-5795","authenticated-orcid":false,"given":"Ruiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8874","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jid.2024.05.018","article-title":"Retracing from outcomes to causes: NRF2-driven GSTA4 transcriptional regulation controls chronic inflammation and oxidative stress in atopic dermatitis recurrence","volume":"145","author":"Ma","journal-title":"J Invest Dermatol"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","journal-title":"Br J Dermatol"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70085","article-title":"Burden of atopic dermatitis in China and its provinces, 1990-2021: a global burden of disease 2021 analysis","volume":"64 Suppl 2","author":"Zhao","journal-title":"Int J Dermatol"},{"issue":"4","key":"R4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2025.06.042","article-title":"Global, regional, and national burdens of atopic dermatitis from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021","volume":"93","author":"Sun","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"R5","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3511","article-title":"Counting the burden: atopic dermatitis and health-related quality of life","volume":"100","author":"Ali","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"R6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017","volume":"184","author":"Laughter","journal-title":"Br J Dermatol"},{"issue":"18","key":"R7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jama.2023.17719","article-title":"Topical therapies for atopic dermatitis","volume":"330","author":"Xu","journal-title":"JAMA"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","article-title":"A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses","volume":"72","author":"Hajar","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","journal-title":"Ann Intern Med"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"R13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","journal-title":"J Am Acad Dermatol"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.18332\/tid\/195380","article-title":"Impact of tobacco smoking and alcohol consumption on the treatment efficacy among psoriasis patients: a study protocol","volume":"22","author":"Shen","journal-title":"Tob Induc Dis"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jdv.16846","article-title":"Measurement properties of the product of investigator\u2019s global assessment and body surface area in children and adults with atopic dermatitis","volume":"35","author":"Silverberg","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"R16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","journal-title":"Br J Dermatol"},{"issue":"10","key":"R17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3530","article-title":"Patient-Oriented Eczema Measure score: a useful tool for web-based surveys in patients with atopic dermatitis","volume":"100","author":"Kido-Nakahara","journal-title":"Acta Derm Venereol"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.2196\/77927","article-title":"Efficacy of WuSheZhiYang pills in mild-to-moderate atopic dermatitis: protocol for a double-blind, randomized, placebo-controlled trial","volume":"14","author":"Gao","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"R19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.anai.2020.12.002","article-title":"Traditional Chinese medicine for food allergy and eczema","volume":"126","author":"Wang","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jep.2010.11.050","article-title":"Topical application of Rehmannia glutinosa extract inhibits mite allergen-induced atopic dermatitis in NC\/Nga mice","volume":"134","author":"Sung","journal-title":"J Ethnopharmacol"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-016-1158-1","article-title":"Characteristics of traditional Chinese medicine users and prescription analysis for pediatric atopic dermatitis: a population-based study","volume":"16","author":"Chen","journal-title":"BMC Complement Altern Med"},{"issue":"8","key":"R22","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/ptr.70020","article-title":"Formononetin from Sophora flavescens Aiton alleviates atopic dermatitis by suppressing neutrophil extracellular traps","volume":"39","author":"Cheng","journal-title":"Phytother Res"},{"issue":"3","key":"R23","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030269","article-title":"Anti-atopic effect of Scutellaria baicalensis and Raphanus sativus on atopic dermatitis-like lesions in mice by experimental verification and compound-target prediction","volume":"17","author":"Lee","journal-title":"Pharmaceuticals (Basel)"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.04.029","article-title":"Glycyrrhizin ameliorates atopic dermatitis-like symptoms through inhibition of HMGB1","volume":"60","author":"Wang","journal-title":"Int Immunopharmacol"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e96094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:23:17Z","timestamp":1785536597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e96094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2196\/96094","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"v15i2e96094"}}